Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, close to half of total revenue is generated within the United States.
| Website: | www.jnj.com |
| Email: | invest@surgeenergy.ca |
| Main Phone: | +1 732 524-0400 |
| Address: | One Johnson & Johnson Plaza |
| Address 2: | Suite 2100 |
| State: | NJ |
| City / Town: | New Brunswick |
| Country: | USA |
| Postal Code: | 08933 |
| Exchange: | NYE |
| CEO: | Alex Gorsky |
| Employees: | 134000 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Gathering Data... Please wait Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, close to half of total revenue is generated within the United States.
| Website: | www.jnj.com |
| Email: | invest@surgeenergy.ca |
| Main Phone: | +1 732 524-0400 |
| Address: | One Johnson & Johnson Plaza |
| Address 2: | Suite 2100 |
| State: | NJ |
| City / Town: | New Brunswick |
| Country: | USA |
| Postal Code: | 08933 |
| Exchange: | NYE |
| CEO: | Alex Gorsky |
| Employees: | 134000 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 136.35 | Change $ 0.66 | Change % 0.49 | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask N/A | Ask Size 0.00 |
| Open 135.97 | High 136.73 | Low 135.73 | Prev Close 135.69 |
| Last Trade | Volume 6.1 mi | 52 Wk Hi 148.99 | 52 Wk Low 118.62 |
| Market Cap 365.7 bi | Ex-Div Date | Div Rate 3.60 | Yield 2.6780 |
| Shares 2,681,977,969.00 | EPS (TTM) 5.61 | PE Ratio 24.00 | Exchange NYSE |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 51 |
| Number of Buys | 0 | 28 |
| Number of Sells | 0 | 23 |
| Net Activity | 0 | 258349 |
| Last 10 Buys | Shares |
|---|---|
| Charles O. Prince | 1,000 |
| Charles O. Prince | 1,000 |
| Charles O. Prince | 1,000 |
| William D. Perez | 1,000 |
| William D. Perez | 1,000 |
| William D. Perez | 1,000 |
| William D. Perez | 1,000 |
| William D. Perez | 1,000 |
| William D. Perez | 1,000 |
| William D. Perez | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Paulus Stoffels | 1,000 |
| Paulus Stoffels | 1,000 |
| Dominic J. Caruso | 1,000 |
| Joaquin Duato | 1,000 |
| Gary J. Pruden | 1,000 |
| Ronald A. Kapusta | 1,000 |
| Paulus Stoffels | 1,000 |
| Michael H. Ullmann | 1,000 |
| Dominic J. Caruso | 1,000 |
| Ronald A. Kapusta | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 161 | 161 | 161 | 161 |
| Low Target Price Estimate | 110 | 110 | 110 | 110 |
| Mean Target Price Estimate | 146.07 | 146.07 | 146.07 | 146.07 |
| Standard Deviation | 12.86 | 12.86 | 12.86 | 12.86 |
| Date of Most Recent Estimate | 05/17/18 | 05/17/18 | 05/17/18 | 05/17/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| SD | Specialized Disclosure Report | 18 | 2018-05-23 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-05-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-07 |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-05-02 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 98 | 2018-05-01 |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-04-30 |
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2018-04-30 |
| 8-K | Report of unscheduled material events or corporate changes. | 20 | 2018-04-17 |
| 8-K | Report of unscheduled material events or corporate changes. | 4 | 2018-03-20 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-03-15 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 8 |
| Moderate Buy | 2 | 2 | 2 | 2 |
| Hold | 6 | 6 | 6 | 6 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 2 | 2 | 2 | 2 |
| Mean Rec. | 2.22 | 2.22 | 2.22 | 2.22 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
